These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34759359)

  • 1. Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis.
    Plavén-Sigray P; Ikonen Victorsson P; Santillo A; Matheson GJ; Lee M; Collste K; Fatouros-Bergman H; Sellgren CM; Erhardt S; Agartz I; Halldin C; Farde L; Cervenka S
    Mol Psychiatry; 2022 Feb; 27(2):1233-1240. PubMed ID: 34759359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis.
    Schifani C; Tseng HH; Kenk M; Tagore A; Kiang M; Wilson AA; Houle S; Rusjan PM; Mizrahi R
    Brain; 2018 Jul; 141(7):2213-2224. PubMed ID: 29860329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.
    Suridjan I; Rusjan P; Addington J; Wilson AA; Houle S; Mizrahi R
    J Psychiatry Neurosci; 2013 Mar; 38(2):98-106. PubMed ID: 23010256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia.
    Buchsbaum MS; Christian BT; Lehrer DS; Narayanan TK; Shi B; Mantil J; Kemether E; Oakes TR; Mukherjee J
    Schizophr Res; 2006 Jul; 85(1-3):232-44. PubMed ID: 16713185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia.
    Yasuno F; Suhara T; Okubo Y; Sudo Y; Inoue M; Ichimiya T; Takano A; Nakayama K; Halldin C; Farde L
    Am J Psychiatry; 2004 Jun; 161(6):1016-22. PubMed ID: 15169689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between excitement symptom severity and extrastriatal dopamine D
    Joo YH; Kim JH; Son YD; Kim HK; Shin YJ; Lee SY; Kim JH
    Eur Arch Psychiatry Clin Neurosci; 2018 Sep; 268(6):529-540. PubMed ID: 28623450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrastriatal dopamine D
    Nørbak-Emig H; Pinborg LH; Raghava JM; Svarer C; Baaré WFC; Allerup P; Friberg L; Rostrup E; Glenthøj B; Ebdrup BH
    World J Biol Psychiatry; 2017 Oct; 18(7):539-549. PubMed ID: 27782768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457.
    Talvik M; Nordström AL; Olsson H; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):361-70. PubMed ID: 14604451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.
    Abi-Jaoude E; Segura B; Obeso I; Cho SS; Houle S; Lang AE; Rusjan P; Sandor P; Strafella AP
    Hum Brain Mapp; 2015 Jul; 36(7):2592-601. PubMed ID: 25788222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia.
    Jauhar S; Nour MM; Veronese M; Rogdaki M; Bonoldi I; Azis M; Turkheimer F; McGuire P; Young AH; Howes OD
    JAMA Psychiatry; 2017 Dec; 74(12):1206-1213. PubMed ID: 29049482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D2/D3 receptor abnormalities after traumatic brain injury and their relationship to post-traumatic depression.
    Jolly AE; Raymont V; Cole JH; Whittington A; Scott G; De Simoni S; Searle G; Gunn RN; Sharp DJ
    Neuroimage Clin; 2019; 24():101950. PubMed ID: 31352218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study.
    Graff-Guerrero A; Mizrahi R; Agid O; Marcon H; Barsoum P; Rusjan P; Wilson AA; Zipursky R; Kapur S
    Neuropsychopharmacology; 2009 Mar; 34(4):1078-86. PubMed ID: 18987627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis.
    Borgan F; Laurikainen H; Veronese M; Marques TR; Haaparanta-Solin M; Solin O; Dahoun T; Rogdaki M; Salokangas RK; Karukivi M; Di Forti M; Turkheimer F; Hietala J; Howes O;
    JAMA Psychiatry; 2019 Oct; 76(10):1074-1084. PubMed ID: 31268519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midbrain dopamine D2/3 receptor binding in schizophrenia.
    Tuppurainen H; Kuikka JT; Laakso MP; Viinamäki H; Husso M; Tiihonen J
    Eur Arch Psychiatry Clin Neurosci; 2006 Sep; 256(6):382-7. PubMed ID: 16783502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients.
    Fagerlund B; Pinborg LH; Mortensen EL; Friberg L; Baaré WF; Gade A; Svarer C; Glenthøj BY
    Int J Neuropsychopharmacol; 2013 Feb; 16(1):23-36. PubMed ID: 22338593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography.
    Talvik M; Nordström AL; Okubo Y; Olsson H; Borg J; Halldin C; Farde L
    Psychiatry Res; 2006 Dec; 148(2-3):165-73. PubMed ID: 17095199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.